Humana Inc

Humana’s new $120 M Defense Health Agency contract, nursing‑leadership partnership, and $5 M social‑determinants push aim to boost revenue, workforce, and community health.

Humana’s latest partnership with Nurses on Boards, new community outreach data, leadership shifts, and credit reaffirmation highlight the company’s focus on workforce development, social responsibility, and financial stability to navigate evolving m…

Humana explores a partnership with Mark Cuban’s Cost‑Plus Drugs to offer direct‑to‑patient, transparent‑pricing mail‑order pharmacy services for Medicare members.

Humana Inc. has secured a favorable ruling in a Medicare Advantage lawsuit, reinforcing its compliance posture and stability of revenue streams, while also continuing to invest in innovation and precision healthcare solutions.

Humana Inc.’s share price has experienced a modest uptick, aligning with the broader market’s upward trajectory, but the company’s underlying fundamentals, including its strong market capitalization and diversified service offerings, suggest a solid…

Humana Inc.’s stock declined 12% due to concerns over tightened Medicare bonus payment criteria, but the company’s CenterWell division secured a strategic acquisition to potentially offset the impact and drive long-term growth.

Humana’s stock surge is a mixed bag for investors, offering both rewards and risks as the company’s market capitalization and price-to-earnings ratio are both substantial and potentially volatile.

Humana Inc’s stock price surged 12% after the company’s financial report revealed higher revenues and a growth outlook, defying the US health insurance industry’s trend of declining profits.

Humana is making significant strides in healthcare and community engagement, but faces challenges in the form of a lawsuit over Medicare star ratings and market fluctuations.

Humana’s stock price has reached a 52-week low of $230.67 USD, down 43% from its peak.